T-Rex files for leveraged SpaceX, Anthropic ETFs ahead of anticipated IPOs

REX Shares and Tuttle Capital filed to launch 2x leveraged ETFs tied to the yet-to-be-issued publicly traded common stock of SpaceX and Anthropic, aiming to piggyback on anticipated 2026 IPOs. The proposed funds would deliver amplified (2x) exposure to two high-profile IPOs, likely increasing investor interest and derivatives/flow activity around those listings. Expect impacts concentrated in positioning, liquidity and tracking risk for these securities rather than broad market moves, with additional regulatory and operational considerations given the instruments reference not-yet-listed shares.

Analysis

The emergence of retail-accessible, leveraged instruments tied to large pre-IPO stories changes pricing mechanics in private markets: it converts idiosyncratic scarcity into tradable, levered demand that can be amplified or unwound within days. Expect private-mark valuation signals to migrate from quarterly secondary prints to intraday public-market flow dynamics, compressing the private-to-public illiquidity premium over a 3–12 month horizon as market makers and allocators arbitrage the new instruments.

On microstructure, dealers hedging levered retail flows will lean on liquid public proxies and index futures, creating predictable directional pressure on a narrow set of comps and on beta/volatility products. That gamma/leverage overlay increases IV in related public equities and makes short-term momentum more exploitable; the highest-convexity windows will be issuance day and the first 30–90 days around any IPO or lockup cliffs.

Tail risks are asymmetric: a failed or delayed IPO, SEC enforcement action, or settlement frictions could force rapid deleveraging, producing multi-standard-deviation basis blows in instruments that are structurally levered and lightly regulated. Conversely, a smooth issuance can rerate beneficiary public names, but that upside is likely concentrated in the first 30–90 days and subject to quick mean reversion as arbitrageurs harvest spreads.

The consensus will treat new tradable exposure as purely additive liquidity for valuation; the contrarian read is that it may instead act as a supply-creating mechanism that reduces scarcity premia, mutes typical IPO pops, and increases the chance of volatility-led drawdowns in adjacent public equities. Position sizing and option protection should be primary considerations over directional conviction for the next 6–12 months.

Key Decisions for Investors

• Long NVDA — buy a 12–18 month call spread (e.g., Jan 2028 450/750C) sized to 2–3% of equity risk; entry 3–6 months ahead of the anticipated IPO window. Rationale: captures asymmetric upside if retail lever pulls AI multiple higher; risk = premium paid, target R/R ~3:1 if a re-rate occurs within 12–18 months.
• Protect aerospace exposure — buy a 3–6 month put spread on RTX (e.g., 5% OTM put spread) sized to offset ~20% of your aerospace/supplier beta. Rationale: limits drawdown from a disorderly deleveraging or weak IPO that spills into supplier CPMs; cost small, payoff 4–6x on a >15% upset in the stock.
• Event-vol hedge — purchase short-dated VIX calls or S&P 500 1–2% put spread covering the 0–60 day windows around any launch or IPO. Size to 1–2% of portfolio; this is cheap insurance for concentrated retail-driven dislocations and has high convexity vs cost.
• Reduce speculative small-cap thematic exposure — cut net long exposure to small-cap/ETF baskets by ~25% into the first issuance and maintain lower allocation for 90 days post-IPO. Rationale: new levered instruments increase short-term dispersion and gamma; lower size reduces forced-selling risk during deleveraging.